1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Xbrane Biopharma AB (publ)
  6. News
  7. Summary
    XBRANE   SE0007789409

XBRANE BIOPHARMA AB (PUBL)

(XBRANE)
  Report
Delayed Nasdaq Stockholm  -  05/25 06:59:34 am EDT
74.70 SEK   +0.40%
05/05Announcement from Xbrane Biopharma's annual general meeting
AQ
05/05TRANSCRIPT : Xbrane Biopharma AB, Q1 2022 Earnings Call, May 05, 2022
CI
05/05Xbrane Biopharma releases interim report for January – March 2022
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

INVITATION TO PRESENTATION OF XBRANE BIOPHARMA'S INTERIM REPORT JANUARY - SEPTEMBER, 2021

10/29/2021 | 10:13am EDT

Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on Friday October 29, 2021, at 10.00 a.m. CET. Xbrane will publish the company's interim report for January - September, 2021, on Friday October 29, 2021, at 8.00 a.m. CET.

Martin Amark, CEO, and Anette Lindqvist, CFO/IR, will present the interim report for January - September 2021, followed by a Q&A session. The presentation will be in English. To attend, please follow the link or dial-in at one of the numbers below:

Web link: https://edge.media-server.com/mmc/p/xp3g5i77

Confirmation Code: 1692076

Standard international: +44 (0) 2071 928 338

UK (Local): +44 (0) 844 481 97 52

UK (Tollfree): +44 (0) 800 279 66 19

Sweden (Local): +46 (0) 856 618 467

Sweden (TollFree): +46 (0) 20 012 51 60

US (Local): +1 646 741 31 67

US (TollFree): +1 877 870 91 35

Contact:

Martin Amark

CEO

M: +46 76 309 37 77

E: martin.amark@xbrane.com

Anette Lindqvist

CFO/IR

M: +46 76 325 60 90

E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane's leading product Xlucane, a Lucentis biosimilar candidate, addresses the EUR 10.4bn ophthalmic VEGFa inhibitor market. Marketing authorization of Xlucane is expected for the second half of 2022. Xbrane has additionally two biosimilar candidates in its pipeline targeting EUR 7.9bn in originator sales. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE.

For more information, visit www.xbrane.com.

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about XBRANE BIOPHARMA AB (PUBL)
05/05Announcement from Xbrane Biopharma's annual general meeting
AQ
05/05TRANSCRIPT : Xbrane Biopharma AB, Q1 2022 Earnings Call, May 05, 2022
CI
05/05Xbrane Biopharma releases interim report for January – March 2022
AQ
05/05Xbrane Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/02Invitation to presentation of Xbrane Biopharma's interim report January – March 2..
AQ
04/05Correction regarding notice of annual general meeting in Xbrane Biopharma
AQ
04/04Notice of annual general meeting in Xbrane Biopharma AB
AQ
03/31Xbrane Biopharma releases annual report 2021
AQ
03/09Xbrane Biopharma - Xciting and Increasingly Compelling Case
AQ
02/24TRANSCRIPT : Xbrane Biopharma AB, Q4 2021 Earnings Call, Feb 24, 2022
CI
More news
Financials
Sales 2021 18,7 M 1,90 M 1,90 M
Net income 2021 -225 M -22,8 M -22,8 M
Net cash 2021 445 M 45,1 M 45,1 M
P/E ratio 2021 -7,60x
Yield 2021 -
Capitalization 1 870 M 189 M 189 M
EV / Sales 2021 76,1x
EV / Sales 2022 5,19x
Nbr of Employees 64
Free-Float 66,3%
Chart XBRANE BIOPHARMA AB (PUBL)
Duration : Period :
Xbrane Biopharma AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends XBRANE BIOPHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 74,70 SEK
Average target price 235,00 SEK
Spread / Average Target 215%
EPS Revisions
Managers and Directors
Martin ┼mark Chief Executive Officer
Anette Lindqvist Chief Financial Officer & Head-Investor Relations
Anders Lennart Tullgren Chairman
David Vikstr÷m Chief Technology Officer
Siavash Bashiri Chief Operating Officer & Head-Biosimilars
Sector and Competitors
1st jan.Capi. (M$)
XBRANE BIOPHARMA AB (PUBL)-28.72%189
MODERNA, INC.-48.48%52 047
LONZA GROUP AG-28.07%42 228
IQVIA HOLDINGS INC.-27.93%38 488
SEAGEN INC.-11.73%25 121
ICON PUBLIC LIMITED COMPANY-31.56%17 232